Corneal Cross-linking: The Only FDA Approved Treatment That Can Prevent Keratoconus From Getting Worse
Corneal collagen cross-linking, also known as KXL or CXL, is a newly FDA approved procedure that helps treat keratoconus by stabilizing the cornea to prevent it from getting weaker and thinner.
What is Keratoconus?
Keratoconus is a progressive eye disease that causes the tissue in the cornea to thin over time. This gradual thinning can cause the normally round cornea to lose its shape, bulging and becoming more cone-like.
As it progresses, keratoconus can result in severe nearsightedness, irregular astigmatism, and light sensitivity, and can cause the patient’s prescription to change with every eye exam.
What is Corneal Cross-linking?
Corneal cross-linking is a treatment where riboflavin drops are placed in the eye, which are then activated using a controlled application of ultraviolet light. This results in an increase of collagen cross-links, which are the natural anchors within the cornea. Strengthening the collagen cross-links prevents the cornea from bulging or losing shape.
The entire procedure will take around 60 minutes to complete. A contact lens is then placed on the eye to protect the cornea for a few days. Patients can expect to see their vision stabilize over the months following the procedure. In many cases, this stabilization after cross-linking could allow you to have a vision correction treatment such as PRK to reduce or eliminate the need for glasses or contact lenses. However, it is important to know that the main goal of cross-linking is to stop or slow changes in the vision due to keratoconus by increasing the stability of the cornea.
The First Center In Oklahoma To Offer This FDA Approved Treatment Technology
In April 2016, the FDA approved the KXL® System for corneal cross-linking, a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light. They are the first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus, and ClearSight is proud to be the first center in Oklahoma to offer this treatment to our patients.
The approval offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.
Corneal Cross-linking (KXL) at ClearSight
Here at ClearSight, our goal isn’t to perform a procedure; it’s to deliver life-changing results. When we recommend cross-linking as your treatment option, our service includes everything you need to get you the best possible outcome. For KXL this includes:
- Your initial Corneal Cross-linking (KXL) Procedure
- Basic follow-up exams for two years so that we can assess healing and stability
- A starter kit of prescription eye drops
- One additional KXL treatment if needed within two years of the initial KXL treatment
- A 20% discount (good for 2 years) on procedures such as PRK or ICL to improve visual quality
If you would like to learn more about cross-linking, or find out if you’re a candidate, please schedule your complimentary eye exam and consultation with us today! Get started by picking your preferred day and time below: